Knowledge about the epidemiology and ecology of SARS coronavirus infection remains presently incomplete and the risk of re-emergence is unpredictable. The rapid spread of SARS worldwide showed the need to maintain surveillance despite the disease’s absence since 2003.
The Annual Epidemiological Report 2014 gives an overview of the epidemiology of communicable diseases of public health significance in Europe, drawn from surveillance information on the 52 communicable diseases and health issues for which surveillance is mandatory in the European Union and European Economic Area countries. The respiratory tract infections chapter from the upcoming ECDC Annual Epidemiological Report 2014 is now available as a separate report and provides a snapshot of the epidemiological situation in Europe across a number of diseases.
New and noteworthy in this update: the retrospective identification of novel coronavirus in biological samples from two fatal cases in Jordan (April 2012) and the results of a joint ECDC/WHO survey which confirms that EU/EEA Member States have an adequate capacity to detect novel coronavirus through their network of national reference laboratories: 18 of 30 in EU/EEA countries are capable of confirming positive screened samples by either ORF1b RT-PCR or other target RT-PCR assays with sequence analysis or whole-genome sequence analysis.
CDC updated risk assessment concludes that in the absence of evidence of sustained person-to-person transmission outside of household settings, the current facts still point towards a hypothesis of a zoonotic or environmental source with occasional transmission to exposed humans. WHO does not advise any travel or trade restrictions at this point for KSA or Qatar.
Severe acute respiratory syndrome (SARS) is a life-threatening respiratory disease caused by a recently identified coronavirus; the SARS-associated coronavirus (SARS-CoV). This is believed to be an animal virus that recently crossed the species barrier to infect humans.
In June 2009, ECDC convened a technical expert consultation that focused on tuberculosis, new emerging airborne diseases (e.g. SARS) and meningococcal infections. This consultation was the second of a two-part process intended to assist national authorities in the EU Member States in the assessment of risks associated with the transmission of various infectious agents on board airplanes.